Pulmonary Drug Delivery and Development

This training program will elucidate pulmonary drug delivery and lung physiology. It will further discuss CMC aspects for lot release and characterization, and comparative routes of drug delivery (pulmonary vs oral).

Why Should You Attend:

This webinar will provide attendees an overview of the lungs as a portal and a preferred route for both local as well as systemic therapeutic strategies for both small as well as macromolecules. Inhaled insulin, first approved in Jan 2006, and then withdrawn from the market by Pfizer due to commercial reasons has seen an increased interest due to Mannkind’s Afrezza (inhaled insulin) approved in March 2014 which has now been partnered with Sanofi for the global market outside the US, while Mannkind retains US rights.

Who Will Benefit:

Senior Management (Decision Makers)

QA/QC, Regulatory

Manufacturing and Analytical Personnel

Research Personnel, Strategy and New Product Planning

Instructor Profile:

Dr. Aditya Das is a CMC and regulatory consultant serving the pharmaceutical industry. He coordinates the interface between client needs and external services/capabilities to facilitate strategic positioning for optimal product development and global registration. Services provided to clients in response to specific requests include regulatory input (chemistry, manufacturing and control sections); risk analysis; cost estimates; process design; and combination (drug/device) product development.

Note:

Use coupon code NB5SQH8N and get 10% off on registration, Valid till Dec 31st 2015.

For Registration:

http://www.complianceonline.com/pulmonary-drug-delivery-and-development-webinar-training-704258-prdw?channel=sciencedz